Exencial Wealth Advisors LLC Sells 140,392 Shares of Edwards Lifesciences Corporation $EW

Exencial Wealth Advisors LLC lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 96.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,123 shares of the medical research company’s stock after selling 140,392 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $437,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of EW. Brighton Jones LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at $266,000. NewEdge Advisors LLC lifted its position in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. lifted its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC lifted its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,704,682.56. The trade was a 51.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 86,058 shares of company stock worth $7,118,636 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price for the company in a report on Wednesday, April 1st. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Wells Fargo & Company raised their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Finally, Robert W. Baird raised their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.65.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $83.55 on Friday. The firm has a 50-day moving average price of $82.08 and a 200-day moving average price of $82.41. The firm has a market capitalization of $48.17 billion, a PE ratio of 44.44, a price-to-earnings-growth ratio of 2.04 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.17%. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the business posted $0.64 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.